In the first survey we were able to collect valuable information on the shortcomings of healthcare and identify the main problems patients faced due to the COVID-19 pandemic.
To find out whether these problems persist or have been solved, we need to know your experience.
Your participation is important to understand the impact of the pandemic on patients with rheumatic diseases and, in this way, to establish measures to reduce the impact and improve the care and quality of life of this group.
After months of effort, the results of the REUMAVID study are beginning to be presented at scientific conferences. For the
The greatest problem for patients with rheumatic diseases in Europe during the COVID-19 pandemic was access to healthcare. 58% of
The REUMAVID study is echoed in Portugal. In 2020, the 23º Foro de Apoyo al Paciente Reumático – New Challenges
After months of effort, the results of the REUMAVID study are beginning to be presented at scientific conferences. For the
The greatest problem for patients with rheumatic diseases in Europe during the COVID-19 pandemic was access to healthcare. 58% of
The REUMAVID study is echoed in Portugal. In 2020, the 23º Foro de Apoyo al Paciente Reumático – New Challenges
REUMAVID is a project conducted by the Health & Territory Research (HTR) group of the University of Seville (Spain)
